Eyevensys Named to French Tech 120 Program
Paris, France, and Cambridge, Mass., United States, October 05, 2020 – Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies…
Paris, France, and Cambridge, Mass., United States, October 05, 2020 – Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies…
Paris, France, and Cambridge, Mass., United States, October 05, 2020 – Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies…
Gerald Cagle, Ph.D. named Chairman of the Board Francine Behar-Cohen, M.D., Ph.D. named Chief Innovation Officer Thierry Bordet, Ph.D. named Chief Scientific Officer Paris, France, and Fort Worth, Texas, United…
Eyevensys announced today that it has completed a $30 million Series B financing. The round was led by Boehringer Ingelheim Venture Fund and included participation from existing investors Pontifax, Bpifrance,…
Eyevensys this week presented results from part 1 of its phase I/II study for non-infectious uveitis (NIU) at the Ophthalmology Innovation Summit’s (OIS) 11th Annual OIS@AAO conference on October 10,…
Eyevensys today announced that Gerald (Jerry) Cagle, Ph.D., former Senior Vice President and Chief Scientific Officer at Alcon Laboratories has joined its Board of Directors. Dr. Cagle is a highly…
Paris (France), December 12th, 2017 – Eyevensys, a clinical stage biotech company developing non-viral gene therapies for ophthalmic diseases, today announced the appointment of Dr. Patricia Zilliox as CEO. Dr.…
Paris (France), 13th September 2017 – Eyevensys, a clinical stage biotech company developing its proprietary EyeCET platform, the first non-viral gene expression technology that enables the safe, local, sustained production…
Paris (France), 4th September 2017 – Eyevensys, a clinical stage biotech company developing its proprietary EyeCET platform, the first non-viral gene expression technology that enables the safe, local, sustained production…
Eyevensys announces today that it has successfully treated the first patient in a first-in-human phase I/II trial of its lead candidate EYS606 for Non-Infectious Uveitis (NIU). The patient was treated…